|
MechanismSARS-CoV-2 S protein inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date08 Dec 2021 |
|
MechanismSARS-CoV-2 S protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date08 Dec 2021 |
100 Clinical Results associated with Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd.
0 Patents (Medical) associated with Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd.
100 Deals associated with Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd.
100 Translational Medicine associated with Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd.